News-Morimatsu LifeSciences

FROM CRITICAL EQUIPMENT TO
TOTAL PROCESS SOLUTION

BACK

Building on Trust, Advancing Digital Intelligence | Zencore Biologics & Morimatsu Mo-EAMaster Phase II Launch

On January 9, 2026, Morimatsu LifeSciences and Zencore Biologics successfully held the Mo-EAMaster Phase II Project Kickoff Meeting. Building on the strong results of Phase I, the two companies are once again collaborating to drive the next stage of digital intelligence upgrades in pharmaceutical as
Decoding the “Impeller Code”: Balancing Mass Transfer and Shear in Cell Plants

In the world of biopharmaceutical manufacturing,Chinese Hamster Ovary (CHO) cellsare the workhorses behind modern antibody drugs—producing nearly 90% of the world’s supply. As demand continues to grow, manufacturers face a familiar challenge: how to scale up high-density cell cultures
Morimatsu LifeSciences 2025 Impressive Moment

About Morimatsu LifeSciencesMorimatsu LifeSciences is a key business segment of Morimatsu International Holdings Limited (Stock Code: 2155.HK).It comprises Shanghai Morimatsu Pharmaceutical Equipment Engineering Co., Ltd., Morimatsu (Suzhou) LifeSciences Co., Ltd., Shanghai Morimatsu Biotechno
Pharmadule Morimatsu Modular Plant Wins the Red Dot Award & French Design Award

About Morimatsu LifeSciencesMorimatsu LifeSciences is a key business segment of Morimatsu International Holdings Limited (Stock Code: 2155.HK).It comprises Shanghai Morimatsu Pharmaceutical Equipment Engineering Co., Ltd., Morimatsu (Suzhou) LifeSciences Co., Ltd., Shanghai Morimatsu Biotechno
Regulatory Insight | A Brief Analysis of CCS Contamination Control Strategies in EU GMP Annex 1 for Sterile Products

The Contamination Control Strategy (CCS) is a central concept in the 2022 EU GMP Annex 1 for Sterile Products, introduced to strengthen quality risk management for sterile pharmaceuticals. Earlier GMP standards relied heavily on terminal sterilization and sterility testing as primary quality assuran

Prev ···2 3 4 5 6··· Next